companydata.dkcompanydata.dk

CONTERA PHARMA A/S: Financial statements 2025

CVR: 33062214

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802. The solvency ratio was 81.5%. The company had 14 employees in the financial year.

Gross Profit
DKK 20,632,306
Profit/Loss
DKK -4,783,781
Equity
DKK 79,471,802
Total Assets
DKK 97,550,947
Employees
14

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025-20.6 mio.-4.8 mio.79.5 mio.14
2024--54.1 mio.-69.2 mio.54.4 mio.19
2023--59 mio.-71.3 mio.86.3 mio.17
2022--44.8 mio.-56.9 mio.106.6 mio.14
2021--24.2 mio.-31.5 mio.163.4 mio.13

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is CONTERA PHARMA A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

CONTERA PHARMA A/S: The 2024 annual report is outMay 19, 2025

CONTERA PHARMA A/S has published its annual report for 2024. Gross profit came to DKK -54,083,946, and the net result was DKK -69,213,744.

Mi Chung Ahn joins the board of CONTERA PHARMA A/SApr 15, 2025

As of April 15, 2025, Mi Chung Ahn has joined the board of directors of CONTERA PHARMA A/S.

Soo Yeon Park leaves the board of CONTERA PHARMA A/SApr 15, 2025

As of April 15, 2025, Soo Yeon Park has left the board of directors of CONTERA PHARMA A/S.

About CONTERA PHARMA A/S

CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The board consists of Jae Young Lee (chair), Jee Hun Kim, Paul Ejnar Gremaud Kristjansen and Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802.

Source: annual report 2025, Danish Business Authority